Nothing Special   »   [go: up one dir, main page]
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.4
4.8
Journals
Biomolecules
Special Issues
Diabetes, Overweight and Obesity: From Molecular Mechanisms to Therapies Strategies
share announcement

Diabetes, Overweight and Obesity: From Molecular Mechanisms to Therapies Strategies

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 7005

Special Issue Editors

Dr. Othmar Moser

E-Mail Website
Guest Editor
Center of Sports Medicine & Sports Orthopedics, University Outpatient Clinic, University of Potsdam, Am Neuen Palais 12, 14469 Potsdam, Germany
Interests: diabetology; exercise; glucose metabolism
Special Issues, Collections and Topics in MDPI journals
Dr. Harald Sourij

E-Mail Website
Guest Editor
Interdisciplinary Metabolic Medicine Trials Unit, Division of Endocrinology and Diabetology, Medical University of Graz, 8010 Graz, Austria
Interests: diabetology; exercise; glucose metabolism
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The aim of this Special Issue is to transfer existing knowledge of molecular mechanisms, obtained via clinical trials, to potential use in the routine care of people with diabetes, overweight, and obesity. In recent years, several novel glucose-lowering drugs have emerged; we do not yet fully understand their mechanisms of action and future roles in clinical treatment regimens. A close interplay between basic, translational, and clinical research is necessary to improve treatment options for people with diabetes, overweight, and obesity. In this context, we invite the submission of manuscripts concerning diabetes, overweight, and obesity. Topics may include but are not limited to

  • Beta cell function and treatment options for enhancing it;
  • The interplay of beta and alpha cells;
  • Treatment options for modulating peripheral and liver insulin sensitivity;
  • Glucose transporter (GLUT) modulation;
  • Novel mechanisms of action of glucose-lowering drugs;
  • Molecular mechanisms related to lifestyle interventions;
  • The pathophysiologic role of the gut microbiome and interventions for modulating the microbiome in metabolic diseases;
  • The role of inflammation in the treatment of diabetes and associated complications;
  • Novel molecules for the treatment of diabetes, overweight, and obesity;
  • The relationship between liver metabolism and diabetes.

Dr. Othmar Moser
Dr. Harald Sourij
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes mellitus
  • overweight
  • obesity
  • molecular mechanisms
  • microbiome
  • liver metabolism
  • advanced therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

9 pages, 442 KiB  
Article
Serum Leucine-Rich Alpha-2 Glycoprotein 1 Levels in Patients with Lipodystrophy Syndromes
by Michelle Krienke, Susan Kralisch, Leonie Wagner, Anke Tönjes and Konstanze Miehle
Biomolecules 2024, 14(11), 1474; https://doi.org/10.3390/biom14111474 - 19 Nov 2024
Cited by 1 | Viewed by 934
Abstract
Serum concentrations of leucine-rich alpha-2 glycoprotein 1 (LRG1) are elevated in several cardio-metabolic and inflammatory diseases. LRG1 also plays an important role in the development of hepatic steatosis and insulin resistance. In lipodystrophies (LDs), severe cardio-metabolic complications can be observed. The dysregulation of [...] Read more.
Serum concentrations of leucine-rich alpha-2 glycoprotein 1 (LRG1) are elevated in several cardio-metabolic and inflammatory diseases. LRG1 also plays an important role in the development of hepatic steatosis and insulin resistance. In lipodystrophies (LDs), severe cardio-metabolic complications can be observed. The dysregulation of several adipokines plays a significant role in the clinical manifestation of this syndrome. To date, there have been no studies of LRG1 levels in non-HIV-LD patients. We performed a cross-sectional analysis of LRG1 serum levels in 60 patients with non-HIV-associated LD and in 60 age-, sex-, and BMI-matched healthy controls. Furthermore, we investigated the gene expression of Lrg1 in a mouse model of generalised LD. No significant difference was found in the median concentration of LRG1 serum levels between LD patients (18.2 ng/L; interquartile range 8.3 ng/L) and healthy controls (17.8 ng/L; interquartile range 11.0 ng/L). LRG1 serum concentrations correlated positively with CRP serum levels (p < 0.001). Lrg1 mRNA expression was downregulated in the adipose tissue, whereas in the liver, no difference in Lrg1 expression between LD and wild-type mice was detected. In summary, circulating levels of LRG1 are associated with low-grade inflammation but cannot distinguish between patients with LD and controls. Full article
(This article belongs to the Special Issue Diabetes, Overweight and Obesity: From Molecular Mechanisms to Therapies Strategies)
►▼ Show Figures

Figure 1

Figure 1
<p>(<b>A</b>,<b>B</b>) The expression of <span class="html-italic">Lrg1</span> in the iWAT and BAT of lipodystrophic SREBP1c-Tg <span class="html-italic">mice</span> (<span class="html-italic">n</span> = 5) was found to be significantly reduced in comparison to wild-type controls (<span class="html-italic">n</span> = 5). (<b>C</b>) Hepatic <span class="html-italic">Lrg1</span> gene expression in SREBP1c-Tg <span class="html-italic">mice</span> exhibited a tendency towards upregulation. Data are presented as means ± SEM. **** <span class="html-italic">p</span> ≤ 0.0001, compared to wild-type controls, unpaired <span class="html-italic">t</span>-test.</p> Full article ">
16 pages, 1504 KiB  
Article
Effect of a Concurrent Training Program with and Without Metformin Treatment on Metabolic Markers and Cardiorespiratory Fitness in Individuals with Insulin Resistance: A Retrospective Analysis
by Jairo Azócar-Gallardo, Alex Ojeda-Aravena, Eduardo Báez-San Martín, Tomás Herrera-Valenzuela, Marcelo Tuesta, Luis González-Rojas, Bibiana Calvo-Rico and José Manuel García-García
Biomolecules 2024, 14(11), 1470; https://doi.org/10.3390/biom14111470 - 19 Nov 2024
Viewed by 1132
Abstract
Background: Type 2 diabetes mellitus is a metabolic disorder characterized by insulin resistance (IR), which is prevalent worldwide and has significant adverse health effects. Metformin is commonly prescribed as a pharmacological treatment. Physical exercise is also recognized as an effective regulator of glycemia, [...] Read more.
Background: Type 2 diabetes mellitus is a metabolic disorder characterized by insulin resistance (IR), which is prevalent worldwide and has significant adverse health effects. Metformin is commonly prescribed as a pharmacological treatment. Physical exercise is also recognized as an effective regulator of glycemia, independent of metformin. However, the effects of inter-day concurrent training (CT)—which includes both endurance and resistance exercises—combined with metformin treatment on metabolic markers and cardiorespiratory fitness in individuals with IR remain controversial. Objective: This study aimed to analyze the effects of a 12-week inter-day CT program on metabolic markers and cardiorespiratory fitness in overweight/obese individuals with IR, both with and without metformin treatment. Additionally, inter-individual responses to CT were examined. Materials and Methods: Data from the 2022–2023 Obesity Center database were retrospectively analyzed. According to the eligibility criteria, 20 overweight/obese individuals diagnosed with IR participated in a 12-week CT program (three weekly sessions: two endurance and one resistance exercise session). Participants were divided into three groups: the exercise group (E-G: n = 7, 32.86 ± 8.32 years, 85.2 ± 19.67 kg), the exercise–metformin group (E-MG: n = 6, 34.83 ± 12.91 years, 88.13 ± 12.66 kg), and the metformin-only control group (M-G: n = 7, 34.43 ± 13.96 years, 94.23 ± 13.93 kg). The M-G did not perform physical exercise during the 12 weeks but continued pharmacological treatment. Body composition, metabolic markers, and cardiorespiratory fitness were assessed before and after the 12-week CT program. Results: A group-by-time interaction was observed for fasting insulin (F2,17 = 34.059, p < 0.001, η2p = 0.88), the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) (F2,17 = 35.597, p < 0.001, η2p = 0.80), and maximal fat oxidation (MFO) (F2,17 = 4.541, p = 0.026, η2p = 0.348) following the CT program. The maximal oxygen uptake (VO2max) showed significant improvements in the E-G (F = 4.888, p = 0.041, ∆+13.3%). Additionally, the percentage of fat mass (%FM) and body mass (BM) were significantly reduced across all groups (F = 125.244, p < 0.001 and F = 91.130, p < 0.001, respectively). The BM decreased by ∆−9.43% in the E-G (five responders, Rs), ∆+9.21% in the EM-G (5 Rs), and ∆+5.15% in the M-G (3 Rs). The %FM was reduced in the E-G by ∆−22.52% (seven Rs). Fasting insulin and the HOMA-IR significantly improved in both the E-G and EM-G, with fasting insulin showing a ∆−82.1% reduction in the E-G (five Rs) and a ∆−85% reduction in the EM-G (six Rs). Similarly, the HOMA-IR improved by ∆+82.6% in the E-G (three Rs) and by ∆+84.6% in the EM-G (six Rs). Conclusions: The 12-week inter-day concurrent training program, whether combined with metformin or not, was similarly effective in improving metabolic markers in patients with insulin resistance as metformin treatment alone. Both exercise groups demonstrated a significant reduction in insulin sensitivity and an increase in maximal fat oxidation. Meanwhile, exclusive pharmacological treatment with metformin markedly decreased cardiorespiratory fitness, and consequently, fat oxidation. Full article
(This article belongs to the Special Issue Diabetes, Overweight and Obesity: From Molecular Mechanisms to Therapies Strategies)
►▼ Show Figures

Figure 1

Figure 1
<p>Group and individual changes before and after the concurrent training program for all group. *: represents statistically changes. (<b>A</b>) body mass; (<b>B</b>) %fat mass, (<b>C</b>) Fasting Insulin; (<b>D</b>) HOMA-IR; (<b>E</b>) Fasting Glycemia; (<b>F</b>) Maximal Fat Oxidation; (<b>G</b>) Maximal Oxygen Uptake.</p> Full article ">Figure 2
<p>Inter-individual variability to concurrent training in the groups analyzed. (<b>A</b>) body mass; (<b>B</b>) %fat mass, (<b>C</b>) Fasting Insulin; (<b>D</b>) HOMA-IR; (<b>E</b>) Fasting Glycemia; (<b>F</b>) Maximal Fat Oxidation; (<b>G</b>) Maximal Oxygen Uptake.</p> Full article ">
18 pages, 3144 KiB  
Article
Effects of Interrupting Prolonged Sitting with Light-Intensity Physical Activity on Inflammatory and Cardiometabolic Risk Markers in Young Adults with Overweight and Obesity: Secondary Outcome Analyses of the SED-ACT Randomized Controlled Crossover Trial
by Sascha W. Hoffmann, Janis Schierbauer, Paul Zimmermann, Thomas Voit, Auguste Grothoff, Nadine B. Wachsmuth, Andreas Rössler, Tobias Niedrist, Helmut K. Lackner and Othmar Moser
Biomolecules 2024, 14(8), 1029; https://doi.org/10.3390/biom14081029 - 19 Aug 2024
Cited by 1 | Viewed by 2093
Abstract
Sedentary behavior (SB) is an essential risk factor for obesity, cardiovascular disease, and type 2 diabetes. Though certain levels of physical activity (PA) may attenuate the detrimental effects of SB, the inflammatory and cardiometabolic responses involved are still not fully understood. The focus [...] Read more.
Sedentary behavior (SB) is an essential risk factor for obesity, cardiovascular disease, and type 2 diabetes. Though certain levels of physical activity (PA) may attenuate the detrimental effects of SB, the inflammatory and cardiometabolic responses involved are still not fully understood. The focus of this secondary outcome analysis was to describe how light-intensity PA snacks (LIPASs, alternate sitting and standing, walking or standing continuously) compared with uninterrupted prolonged sitting affect inflammatory and cardiometabolic risk markers. Seventeen young adults with overweight and obesity participated in this study (eight females, 23.4 ± 3.3 years, body mass index (BMI) 29.7 ± 3.8 kg/m2, glycated hemoglobin A1C (HbA1c) 5.4 ± 0.3%, body fat 31.8 ± 8.2%). Participants were randomly assigned to the following conditions which were tested during an 8 h simulated workday: uninterrupted prolonged sitting (SIT), alternate sitting and standing (SIT-STAND, 2.5 h total standing time), continuous standing (STAND), and continuous walking (1.6 km/h; WALK). Each condition also included a standardized non-relativized breakfast and lunch. Venous blood samples were obtained in a fasted state at baseline (T0), 1 h after lunch (T1) and 8 h after baseline (T2). Inflammatory and cardiometabolic risk markers included interleukin-6 (IL-6), c-reactive protein (CRP), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TGs), visceral fat area (VFA), triglyceride-glucose (TyG) index, two lipid ratio measures, TG/HDL-C and TC/HDL-C, albumin, amylase (pancreatic), total protein, uric acid, and urea. We found significant changes in a broad range of certain inflammatory and cardiometabolic risk markers during the intervention phase for IL-6 (p = 0.014), TG (p = 0.012), TC (p = 0.017), HDL-C (p = 0.020), LDL-C (p = 0.021), albumin (p = 0.003), total protein (p = 0.021), and uric acid (p = 0.040) in favor of light-intensity walking compared with uninterrupted prolonged sitting, alternate sitting and standing, and continuous standing. We found no significant changes in CRP (p = 0.529), creatinine (p = 0.199), TyG (p = 0.331), and the lipid ratios TG/HDL-C (p = 0.793) and TC/HDL-C (p = 0.221) in response to the PA snack. During a simulated 8 h work environment replacement and interruption of prolonged sitting with light-intensity walking, significant positive effects on certain inflammatory and cardiometabolic risk markers were found in young adults with overweight and obesity. Full article
(This article belongs to the Special Issue Diabetes, Overweight and Obesity: From Molecular Mechanisms to Therapies Strategies)
►▼ Show Figures

Figure 1

Figure 1
<p>Participant flow chart.</p> Full article ">Figure 2
<p>Study protocol: (<b>a</b>) overview of the study design; (<b>b</b>) overview of the trial visits. Participants (<span class="html-italic">n</span> = 17) completed four trial visits in a randomized order separated by one week. Venous blood samples were collected fasted at T<sub>0</sub>, T<sub>1</sub>, and T<sub>2</sub>. Meals were provided at 08.30 a.m. and 12.00 p.m. BIA, bioelectric impedance analysis; OGTT, oral glucose tolerance test; QUE, questionnaire; SIT, uninterrupted prolonged sitting; SIT/STAND, alternate sitting and standing; STAND, continuous standing; WALK, continuous walking.</p> Full article ">Figure 3
<p>Changes in inflammatory and cardiometabolic risk markers studied in each condition Δ1(T<sub>1</sub>−T<sub>0</sub>) as follows: (<b>a</b>) interleukin-6 (IL-6); (<b>b</b>) total cholesterol (TC); (<b>c</b>) high-density lipoprotein cholesterol (HDL-C); (<b>d</b>) low-density lipoprotein cholesterol (LDL-C); (<b>e</b>) triglyceride (TG); (<b>f</b>) albumin; (<b>g</b>) amylase, pancreatic; (<b>h</b>) total protein; (<b>i</b>) uric acid; (<b>j</b>) urea. * <span class="html-italic">p</span> ≤ 0.05; ** <span class="html-italic">p</span> ≤ 0.01; *** <span class="html-italic">p</span> ≤ 0.001.</p> Full article ">Figure 4
<p>Changes in inflammatory and cardiometabolic risk markers studied in each condition Δ2(T<sub>2</sub>−T<sub>0</sub>) as follows: (<b>a</b>) interleukin-6 (IL-6); (<b>b</b>) total cholesterol (TC); (<b>c</b>) high-density lipoprotein cholesterol (HDL-C); (<b>d</b>) low-density lipoprotein cholesterol (LDL-C); (<b>e</b>) triglyceride (TG); (<b>f</b>) albumin; (<b>g</b>) amylase, pancreatic; (<b>h</b>) total protein; (<b>i</b>) uric acid; (<b>j</b>) urea. * <span class="html-italic">p</span> ≤ 0.05; ** <span class="html-italic">p</span> ≤ 0.01.</p> Full article ">Figure 5
<p>Changes in inflammatory and cardiometabolic risk markers studied in each condition Δ3(T<sub>2</sub>−T<sub>1</sub>) as follows: (<b>a</b>) interleukin-6 (IL-6); (<b>b</b>) total cholesterol (TC); (<b>c</b>) high-density lipoprotein cholesterol (HDL-C); (<b>d</b>) low-density lipoprotein cholesterol (LDL-C); (<b>e</b>) triglyceride (TG); (<b>f</b>) albumin; (<b>g</b>) amylase, pancreatic; (<b>h</b>) total protein; (<b>i</b>) uric acid; (<b>j</b>) urea. * <span class="html-italic">p</span> ≤ 0.05; ** <span class="html-italic">p</span> ≤ 0.01.</p> Full article ">

Review

Jump to: Research

17 pages, 1616 KiB  
Review
Roles of Mitochondrial Dysfunction in Diabetic Kidney Disease: New Perspectives from Mechanism to Therapy
by Yichen Yang, Jiahui Liu, Qiling Shi, Buyu Guo, Hanbing Jia, Yuxuan Yang and Songbo Fu
Biomolecules 2024, 14(6), 733; https://doi.org/10.3390/biom14060733 - 20 Jun 2024
Cited by 2 | Viewed by 2138
Abstract
Diabetic kidney disease (DKD) is a common microvascular complication of diabetes and the main cause of end-stage renal disease around the world. Mitochondria are the main organelles responsible for producing energy in cells and are closely involved in maintaining normal organ function. Studies [...] Read more.
Diabetic kidney disease (DKD) is a common microvascular complication of diabetes and the main cause of end-stage renal disease around the world. Mitochondria are the main organelles responsible for producing energy in cells and are closely involved in maintaining normal organ function. Studies have found that a high-sugar environment can damage glomeruli and tubules and trigger mitochondrial dysfunction. Meanwhile, animal experiments have shown that DKD symptoms are alleviated when mitochondrial damage is targeted, suggesting that mitochondrial dysfunction is inextricably linked to the development of DKD. This article describes the mechanisms of mitochondrial dysfunction and the progression and onset of DKD. The relationship between DKD and mitochondrial dysfunction is discussed. At the same time, the progress of DKD treatment targeting mitochondrial dysfunction is summarized. We hope to provide new insights into the progress and treatment of DKD. Full article
(This article belongs to the Special Issue Diabetes, Overweight and Obesity: From Molecular Mechanisms to Therapies Strategies)
►▼ Show Figures

Figure 1

Figure 1
<p>The mechanism of mitochondrial dysfunction. Reactive oxygen species (ROS) are mainly generated by the mitochondrial electron respiration chain. When a large amount of reactive oxygen species is produced, cells maintain dynamic balance by regulating mitochondrial biogenesis and autophagy. In terms of dynamics, mitochondria maintain their normal morphology through Drp1-mediated cleavage and Mfn1-, Mfn2-, and Opa1-mediated fusion. The disruption of any of the above links can lead to mitochondrial dysfunction.</p> Full article ">Figure 2
<p>The progression of diabetic nephropathy. Under normal circumstances, the glomerular filtration membrane is composed of an inner to outer layer of endothelial cells, basement membrane, and podocytes. A high-glucose environment can activate the cGAS–STING pathway and NLRP3 inflammasome, leading to pathological changes such as podocyte loss and apoptosis, epithelial cell damage, and foot process fusion. There will be manifestations of tubular cell proliferation, hypertrophy, and interstitial fibrosis in the renal tubules. These are all related to the production of proteinuria.</p> Full article ">Figure 3
<p>Diabetic kidney disease and mitochondrial dynamics disorder. (<b>A</b>) The damage mechanism of mitochondrial lysis in podocytes under a high-glucose environment. (<b>B</b>) The protective mechanism of reducing mitochondrial lysis in tubular cells under a high-glucose environment.</p> Full article ">
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop